NCT00532415View on ClinicalTrials.gov

Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Vitrectomy
Interventions
DRUG

Triamcinolone Acetonide Injectable Suspension

Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00532415 - Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy | Biotech Hunter | Biotech Hunter